Trials Offered by a Specific Doctor

Mark Stein, MD
Dr. Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in field of genitourinary oncology – treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer as well as in men with more advanced prostate cancer. He is also helping to lead two national trials in kidney cancer sponsored by the National Cancer Institute.

Dr. Stein received his B.S. in Molecular Biophysics and Biochemistry from Yale University. He earned his medical degree at New York Medical College, receiving the graduation award in oncology for his published research. He completed a residency in internal medicine at Montefiore Medical Center, and a fellowship in Hematology and Medical Oncology at Mount Sinai Medical Center. Prior to joining Columbia University, Dr. Stein practiced genitourinary oncology for 13 years at Rutgers University and has been an author on over 60 publications including guidelines for assessing the efficacy of new drugs in prostate cancer and recommendations for the use of immunotherapy to treat prostate cancer.

Clinical Studies Managed By Dr. Stein:
More InfoTitleSponsorIRB Number
DetailsStudy of Safety of New Investigational Study Drug Alone and with Nivolumab in Advanced Solid TumorsBristol-Myers SquibbAAAR6275
DetailsStudy of Drug (XmAb20717) in Subjects with Advanced Solid Tumors (DUET-2) - Melanoma, Breast Cancer, Lung Cancer, Stomach CancerXencor, Inc.AAAR8229
DetailsA Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)Seattle Genetics, Inc.AAAR9129
DetailsNKTR-214 in Combination with Pembrolizumab or Atezolizumab in Patients with Advanced or Metastatic Cancer (NSCLC, Bladder, or Melanoma)Nektar TherapeuticsAAAR9278
DetailsStudy of Vaccine (GEN-009) in Adult Patient with Melanoma, NSCLC, Head and Neck Cancer, Bladder Cancer, or Kidney CancerGenocea BiosciencesAAAR9463
DetailsIRONMAN: International Registry for Men with Advanced Prostate CancerThe Prostate Cancer Clinical Trials Consortium PCCTCAAAS1811
DetailsStudy of HPN424 in Patients With Advanced Prostate CancerHarpoon TherapeuticsAAAR8201
DetailsStudy of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerBristol-Myers SquibbAAAS0351
DetailsStudy of androgen deprivation therapy followed by chemoimmunotherpy for newly metastatic hormone-sensitive prostate cancer (mHSPC)Regeneron PharmaceuticalsAAAS1863
DetailsA Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)Xencor, Inc.AAAS3456
DetailsStudy of XmAb22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)Xencor, Inc.AAAS3476
DetailsA Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients with Prostate CancerTmunity Therapeutics, Inc.AAAS6101